New AI-powered research suggests that GLP-1 drugs, commonly used for diabetes and obesity, could prevent up to 34,000 heart attacks and strokes annually by offering cardiovascular benefits to millions of Americans.

Eli Lilly reduces the price of its obesity medication, Zepbound®, offering discounted single-dose vials to expand access for self-pay patients with an on-label prescription. Learn more about this cost-cutting initiative.

Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.

New analysis reveals 85% of individuals stop using GLP-1 drugs for weight loss after two years. Learn about adherence trends and the role of fitness centers like Equinox and MIORA by Life Time in obesity management.

Discover how Ozempic and other GLP-1 agonists may reduce the risk of obesity-associated cancers in a recent study of obese patients. Learn more about the potential cancer-preventive effects of these diabetes medications.

Form Health, a leading provider of science-based obesity care in the U.S., secures $38 million in Series B funding to expand enterprise partnerships, hire ABOM-certified physicians, and enhance telehealth technology.

Discover how genetics affect your exercise needs for obesity prevention. A groundbreaking study reveals why some need to walk more steps daily based on their genetic risk. Learn how personalized step counts can revolutionize obesity management.